SynthesisToxicology and applied pharmacology2013
Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.
Synthesis in Toxicology and applied pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Neurobehavioural effects of developmental toxicity.The Lancet. Neurology · 2014Pooled it
- Bridging global diversity gaps in Parkinson disease research.Nature reviews. Neurology · 2026Review
- Opicapone in Parkinson's disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Review
- Trichloroethylene Exposure and Parkinson's Disease: Environmental Risk, Metabolic Pathways, and Mechanistic Insights.Molecular neurobiology · 2025Review
- Prodromal Parkinsonian Features in Carriers of Gaucher Disease Compared to Controls.Life (Basel, Switzerland) · 2025Article
- Tetrylpyamethrazine alleviates hepatic fibrosis induced by experimental mansonic schistosomiasis.Inflammopharmacology · 2025Article
- The global rise in Parkinson's disease: a critical analysis of causes and future directions.Frontiers in public health · 2025Article
- Review
- Parkinson's disease and occupational exposure to organic solvents in Finland: a nationwide case-control study.Scandinavian journal of work, environment & health · 2024Article
- [The exposome in the context of preventive measures for Alzheimer's and Parkinson's diseases].Der Nervenarzt · 2023Review
- Effect Modification between Genes and Environment and Parkinson's Disease Risk.Annals of neurology · 2022Review
- Towards Substitution of Hexane as Extraction Solvent of Food Products and Ingredients with No Regrets.Foods (Basel, Switzerland) · 2022Review
- The epigenetic mechanisms involved in mitochondrial dysfunction: Implication for Parkinson's disease.Brain pathology (Zurich, Switzerland) · 2022Review
- Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.International journal of molecular sciences · 2022Review
- Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.Neurobiology of disease · 2022Review
- CaFrontiers in cellular neuroscience · 2022Review
- Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target.International journal of molecular sciences · 2021Review
- Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.Archives of pharmacal research · 2021Review
- Solvent exposed occupations and risk of Parkinson disease in Finland.Clinical parkinsonism & related disorders · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Parkinson disease (PD) is a debilitating neurodegenerative motor disorder, with its motor symptoms largely attributable to loss of dopaminergic neurons in the substantia nigra. The causes of PD remain poorly understood, although environmental toxicants may play etiologic roles. Solvents are widespread neurotoxicants present in the workplace and ambient environment. Case reports of parkinsonism, including PD, have been associated with exposures to various solvents, most notably trichloroethylene (TCE). Animal toxicology studies have been conducted on various organic solvents, with some, including TCE, demonstrating potential for inducing nigral system damage. However, a confirmed animal model of solvent-induced PD has not been developed. Numerous epidemiologic studies have investigated potential links between solvents and PD, yielding mostly null or weak associations. An exception is a recent study of twins indicating possible etiologic relations with TCE and other chlorinated solvents, although findings were based on small numbers, and dose-response gradients were not observed. At present, there is no consistent evidence from either the toxicological or epidemiologic perspective that any specific solvent or class of solvents is a cause of PD. Future toxicological research that addresses mechanisms of nigral damage from TCE and its metabolites, with exposure routes and doses relevant to human exposures, is recommended. Improvements in epidemiologic research, especially with regard to quantitative characterization of long-term exposures to specific solvents, are needed to advance scientific knowledge on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.